STAT+: Raleigh-Durham challenges Boston as biomanufacturing hub of the future
MORRISVILLE, N.C. — Ten minutes from the Raleigh airport, the future of biotech is under…
Category: biotechnology
Novavax is on thin ice, and the latest update isn’t exactly encouraging
Want to stay on top of the science and politics driving biotech today? Sign up to…
STAT+: Can gene therapies make for a profitable business? Keep your eye on Bluebird Bio
Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy…
STAT+: Obscure vertigo drug could bring rare hope for patients with devastating neuron disease
About a decade ago, Tatiana Bremova-Ertl’s graduate adviser was studying an obscure, 1950s-era French vertigo…
STAT+: Judge skeptical of arguments against Medicare drug price negotiation
WILMINGTON, Del. — Today was the first time that a federal judge asked questions in-person…
Pfizer’s reset year starts with a little profit
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Years after a polarizing approval, Biogen walks away from Aduhelm
Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval…
STAT+: Vertex pain drug results met with measured optimism — and questions — by observers and experts
Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that…
STAT+: CMS will use outcomes-based agreements in bid to help Medicaid pay for sickle cell gene therapies
In response to concerns over multimillion-dollar price tags for new gene therapies for sickle cell…
STAT+: Here are the new hotspots for Boston-area biotech
Move over, Kendall Square. Folks in the biotech nerve center may shudder at the notion….
How an immunological Trojan horse could treat disease
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Vertex’s closely-watched pain relief drug succeeds in late-stage trials — with a catch
A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company…
STAT+: Cour Pharmaceuticals, a biotech taking aim at autoimmune diseases, raises $105 million
John Puisis was dubious when he first heard about the autoimmune science being developed by…
STAT+: Ultima Genomics launching high-end DNA sequencers that can read genome for $100
Ultima Genomics, an upstart some observers have called a “dark horse” in the world of…
STAT+: FDA’s Woodcock reflects on more than 30 years at agency — and hints at what’s next
WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime…
23andMe breach targeted Chinese, Jewish populations
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Pricey sickle cell treatments raise daunting new challenges for Medicaid programs
Living with sickle cell disease has not been easy on Kourtney Cunningham. The genetic blood…
Eli Lilly overtakes Tesla in market value
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Merck CEO refused to testify in Senate because he’s not an expert in drug pricing, Bernie Sanders says
WASHINGTON — Sen. Bernie Sanders on Thursday jabbed the CEO of Merck for telling congressional…
Listen: The plight of the VC, Gilead’s latest setback, & more M&A
Are venture capitalists OK? Are bolt-ons good for business? And when is it safe to…
Another step toward new drugs for Parkinson’s
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: As biotech VCs struggle to raise money, some debate whether the worst is over
Over the last year or two, something curious has started occurring in the conference rooms…
STAT+: What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s surprising rise
Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura…
Lilly’s gene therapy restores hearing in an 11-year-old, paving way for more treatment
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Ahead of Medicare drug price reform, pharma’s drug pricing has a Streisand effect
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Sanofi scoops up U.S. biotech Inhibrx for up to $2.2 billion as it seeks to bolster pipeline
LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday…
Investigators fault Lilly plant for manufacturing issues
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Gilead’s Trodelvy fails in lung cancer and raises new questions on antibody drug conjugate drugs
Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy,…
Feds bar Theranos founder Elizabeth Holmes from government health programs
WASHINGTON — Theranos founder and ex-CEO Elizabeth Holmes is banned from federal health programs for…
The Senate health committee looks into its first subpoena in 40 years
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Biotech layoffs, slumping stocks, and a 2024 preview
Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going…
STAT+: CRISPR-edited pig liver from eGenesis passes first test in brain-dead human, researchers say
For three days in December, an ICU room at the Hospital of the University of…
The XBI comedown after JPM
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Copay coupons for some drugs must count toward deductibles, after Biden court move
WASHINGTON — Insurers will have to count drug copay coupons toward deductibles and patient spending…
The big any-day-now biotech news we’re keeping an eye on
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Hair loss is one of the most hated chemotherapy side effects. A new biotech hopes to prevent it
The chemotherapy Christine Ko was prescribed for her breast cancer is pretty much a guarantee…
STAT+: Dewpoint Therapeutics cuts 15% of staff, acknowledges Merck, Pfizer broke off partnerships over buzzy science
Dewpoint Therapeutics, the buzziest startup trying to tackle a new field of biology called biomolecular…
STAT+: FDA expands approval of CRISPR-based medicine to treat beta thalassemia
The Food and Drug Administration on Tuesday approved a CRISPR-based medicine to treat beta thalassemia,…
.jpg)
STAT+: Survey: Confusion over key requirements means clinical trials aren’t registered and results aren’t reported
More than half of those responsible for registering clinical trials and reporting results fail to…
The four biotech stories you need to read this morning
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: For-profit biomedical institute, backed by billionaires, launches in Cambridge to speed drug discovery
A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical…
Novartis reportedly decides to pass on Cytokinetics
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT Virtual Event | 2024 JPM Recap, Live!
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET….
The highs — and lows — of JPM 2024 you should pay attention to
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
Listen: Live! From JPM 2024
Is biotech back from its downturn? Can Nvidia solve biology? And is it wise to…
STAT+: A biotech reporter’s notebook: Sunshine rains down on San Francisco
SAN FRANCISCO — It seemed like there was a point during last year’s J.P. Morgan…
JPM Day 3 had a cautiously optimistic outlook
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
STAT+: At JPM, Verve details plot to take genome editing mainstream
SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines…
JPM Day 2 has arrived. Here are the can’t-miss moments of the event so far
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
STAT+: FDA’s Peter Marks seems inclined to grant full approval to Sarepta’s Duchenne gene therapy
SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies,…